GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

ValiRx VAL.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

0.14p

0.00%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ValiRx

Its shares trade on LSE under the ticker VAL.L. It has been listed since 28 February 2000. In the fiscal year to 31 December 2025, it reported revenue of £31,372 and a net loss of £2.2m. At that date it held total assets of £2.6m and shareholders' equity of £2.9m.

ValiRx Plc operates as a biopharmaceutical company. The company is headquartered in Nuneaton, Warwickshire. The company went IPO on 2000-02-28. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. The company focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. The company operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Feb 2000
Employees
11
Website
valirx.com ↗

Leadership

Pay as last reported

  • Mr. Martin GouldstoneNon-Executive Independent Chairman of the Board£26,269
  • Dr. Mark EcclestonChief Executive Officer, Director, since 2024£51,613
  • Mr. Gerald DeslerChief Financial Officer, Executive Director, Company Secretary, since 2006£66,450
  • Ms. Zai AhmadPreclinical Project Manager
  • Ms. Michelle BarnardDirector of Research
  • Dr. Andrew CarnegieHead of Strategic Commercial Development
  • Mr. Kumar NawaniHead of Operations
  • Mr. Mark TreharneCorporate Development Manager
  • Dr. Catherine Tralau-StewartNon-Executive Director, since 2022£12,700

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ValiRx PLC possesses the following strengths that contribute to its competitive advantage in the market:

Weaknesses

  • Despite its overall strength, ValiRx PLC faces the following weaknesses:

Opportunities

  • ValiRx PLC can capitalize on the following opportunities to enhance its market position:

Threats

  • ValiRx PLC must address the following threats to mitigate potential risks to its business:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.